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Methylene-linked bis-phenylbenzimidazoles as a new scaffold for 
interaction with the telomeric DNA/RNA hybrid duplex 
M. K. Islam,a,b P. J. M. Jackson,a,c D. E. Thurstona* and K. M. Rahmana* 
We report here a series of novel methylene-linked bis-
phenylbenzimidazoles intercalators that stabilize telomeric 
DNA/RNA hybrid (tDRH) structures by up to 7.2C at a 1 µM 
ligand concentration while having negligible affinity for 
DNA/DNA duplexes, although with a low affinity for quadruplex 
DNA.  We have used molecular modelling studies to rationalize 
this selectivity, concluding that the methylene spacer between the 
terminal benzimidazole and phenylene moieties plays a key role 
in facilitating the bis-intercalating process.  
 
The DNA/RNA hybrid (DRH) duplex structure (Figure 1b) 
was first proposed six years after the double-helical structure of 
DNA (Figure 1a) was reported by Watson and Crick.1 The first 
DRH duplex was identified in 1961 by annealing a RNA strand 
with a complementary DNA strand2, and the first DRH duplex 
was synthesized in 1960 by reacting oligodeoxythymidylic acid 
with polyriboadenylic acid3. In 1967, X-ray diffraction and CD 
spectroscopy studies confirmed the different conformation of the 
RNA/DNA hybrid structure compared to duplex DNA.4 
 
In cells, DRH duplex formation is an important component 
of the mechanism for elongation of the telomeric DNA sequence 
at the ends of chromosomes.  Telomeres exist as a protein-DNA 
composite with long repeats of a unique six base sequence (5´-
TTAGGG). Upon activation of telomerase, the protein hTERT, 
which contains an RNA sequence (3´-CAAUCCCAAUC-5´) as 
part of its structure, forms an RNA-DNA duplex with one of the 
repeating telomeric 5´-TTAGGG sequences on the 3´-strand of a 
chromosome.5  DNA polymerization then proceeds via reverse 
transcription of part of the RNA template to synthesize one 
telomeric repeat (TTAGGG) on the 3´-end of the DNA primer.  
The DRH duplex formed is thus a unique structure in cells, and 
is considered a high-value drug target in oncology.6 One 
therapeutic approach is to identify small molecules capable of 
stabilizing the tDRH duplex, thus preventing telomere extension.  
Other approaches have attempted to modulate substrate/enzyme 
interaction, and/or inhibit dissociation of the enzyme from the 
substrate.7, 8 
Figure 1: Common forms of DNA: (a) DNA/DNA Duplex (B-
Form), (b) DNA/RNA hybrid duplex (A-Form), and (c) DNA 
quadruplex. 
 
A number of molecules have been reported to bind to non-
telomeric DRH duplexes such as ethidium derivatives, 
ellipticine, paramomycin, ribostamycin and neomycin (S1, 
ESI).9-13 In 2010, Wheelhouse and co-workers reported a 
pyrimidine-connected bis-sulfane molecule (Figure 2) with a 
20-fold preference for binding to a poly(dA)-poly(rU) hybrid 
duplex compared to an equivalent RNA fragment, a 3-fold 
preference over duplex DNA, and 7-fold preference over the 
alternative poly(rA)-poly(dT) hybrid sequence, in a competition 
dialysis assay.13 
 
 
 
 
Figure 2: Molecule reported by Wheelhouse and co-workers 
with an affinity for poly(dA)-poly(rU) hybrid duplex.13 
 
Through screening 2307 molecules from the NCI’s Diversity 
Set II, Natural Products Set II and Mechanistic Diversity Set 
libraries against a telomeric DRH duplex sequence (tDRH, i.e., 
5´-TTA-GGG-TTA-GGG-TTT-TTT-CCC-UAA-CCC-UAA-
aInstitute of Pharmaceutical Science, School of Cancer and Pharmaceutical 
Sciences, King’s College London, London SE1 9NH, United Kingdom. 
bDepartment of Pharmaceutical Chemistry, University of Dhaka, Dhaka-1000, 
Bangladesh. 
CPresently at Femtogenix Ltd, BioPark, Broadwater Road, Welwyn Garden City AL7 
3AX, United Kingdom. 
Email: k.miraz.rahman@kcl.ac.uk (KMR), david.thurston@kcl.ac.uk (DET); Tel: +44 
(0) 207 848 7507 
Electronic Supplementary Information (ESI) available: Experimental procedures, 
and supplemental tables, spectra and graphs. See DOI: 10.1039/x0xx00000x 
COMMUNICATION Journal Name 
2 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
3´), we identified a bis-2-methylquinoline structure 
(NSC273829) (Figure 3) capable of stabilizing the telomeric 
DRH sequence by 11.5°C and 3C at 5 μM and 1 μM, 
respectively, but with negligible affinity for DNA duplex (i.e., 
Tm = 0.6C for a 1 μM ligand concentration). This compound 
was one of a set of thirteen molecules previously reported to have 
G-quadruplex binding affinity.14 The compound was originally 
reported by the NCI to have anticancer activity in mouse L1210 
Leukaemia xenografts15 and to be active against leishmania16. 
 
 
 
Figure 3: Structural features of NSC273829. 
 
Our molecular modelling studies suggested that NSC273829 
has the potential to interact with the tDRH duplex through its 
minor groove, but it does not have the appropriate 3-dimensional 
shape for intercalation unlike previously reported tDRH 
targeting molecules such as the ethidium derivatives and the 
ellipticines.  Therefore, modelling was used to design analogues 
of NSC273829 potentially capable of a greater affinity with the 
tDRH duplex through an intercalative mechanism.  This was 
achieved by incorporating a methylene-based spacer between the 
terminal bis-intercalating groups that included phenyl groups to 
enhance intercalation and to facilitate orientation of the terminal 
benzimidazoles toward the DNA bases.  In an initial study, 
molecular modelling suggested that the 1-benzyl-1H-
benzo[d]imidazole moiety could fit into the telomeric 
DNA/RNA hybrid duplex.  A benzimidazole moiety was also 
chosen because this class of heterocycle is associated with a wide 
spectrum of biological activities.17-19  Moreover, benzimidazoles 
offer additional hydrogen binding opportunities with DNA/RNA 
bases compared to the quinoline moiety present in NSC273829.  
A set of molecules (Library 1) was designed using this 
approach, with the 1-benzyl-1H-benzo[d]imidazole units linked 
by methylene spacers containing 5-10 carbons (Figure 4). 
 
 
 
Figure 4: Structural features of Library 1 molecules. 
 
All Library 1 molecules were synthesized through a simple 
amide coupling reaction. A solution of 4-((1H-
benzo[d]imidazol-1-yl)methyl)benzoic acid (0.20 mmol) in 
dimethylformamide (7 mL) was treated with 1-
hydroxybenzotriazole (0.40 mmol) and N,N'-
diisopropylcarbodiimide (0.35 mmol) at room temperature. After 
an initial activation step to form the activated acid ester (usually 
20-30 minutes), the respective diamines containing 4 to 10 
methylene spacers (0.24 mmol) were added to the reaction 
mixture, which was allowed to stir overnight (14-15 h). Upon 
confirmation of product formation by LC-MS, the reaction was 
quenched with water (10 mL) and extracted with ethyl acetate (3 
x 20 mL) (S2, ESI). All final products were purified by column 
chromatography, and characterised by NMR and MS, and were 
>95% pure based on analysis in two solvent systems using LC-
MS. 
 
 A FRET melting assay (S3, ESI) was carried out as a 
preliminary biophysical screen, and compound 4 (containing 
eight methylenes; Figure 4, n=8) was observed to have a 9-fold 
selectivity for the tDRH duplex compared to the control DNA 
duplex (cDD), stabilizing the hybrid duplex by ΔTm values of 9.5 
and 7.2C at 2 μM and 1 μM, respectively (Table 1). It was 
observed from these studies that molecules containing an even 
number of methylene groups linking the benzimidazole moieties 
stabilised the tDRH to a greater extent. For example, in the case 
of compound 4 (eight methylenes), it provided greater 
stabilization than 5 (nine methylenes), with a difference of 2.7°C 
observed (i.e., 7.2°C compared to 4.5°C). A similar pattern was 
observed for compound 6 (containing ten methylenes) compared 
to 5, with 6 stabilising tDRH to a greater extent (i.e., 6.8°C for 6 
compared to 4.5°C for 5, a difference of 1.7°C). Compounds 
were also screened for binding to the RNA/RNA duplex (RRH; 
i.e., 5´-UUA-GGG-UUA-GGG-UUU-UUU-CCC-UAA-CCC-
UAA-3´), but failed to effect significant stabilisation (i.e., ΔTm 
values ≤0.5°C). 
 
Table 1: Comparison of analogues in terms of FRET and CD studies. 
Library Compound 
tDRH F21T cDD 
ΔTm CD ΔTm CD ΔTm CD 
NCI NSC273829 3.2 - 11.8 - 0.6 - 
1 1 2.4 -- 5.8 -- 0.6 -- 
1 3 4.5 -- 5.5 -- 1.3 -- 
1 4 7.2 ++ 6.5 -- 0.8 -- 
1 5 4.5 -- 6.5 -- 1.2 -- 
1 6 6.8 ++ 6.2 -- 0.9 -- 
2 7 0.5 -- 0.2 -- 0.3 -- 
3 12 0.4 -- 0.3 -- 0.2 -- 
4 17 0.5 -- 0.5 -- 0.3 -- 
ΔTm are at 1 μM ligand concentration, ‘++’ indicates CD shifts, 
‘--’ indicates no shifts in the CD analysis, and “-“ indicates that 
the compound was not evaluated.  Data for 2 μM in S3, ESI.  
 
Library 1 molecules were also screened in the FRET assay 
for binding to the telomeric quadruplex sequence (F21T, 5´d-
FAM-GGG-TTA-GGG-TTA-GGG-TTA-GGG-TAMRA-3´) 
(Table 1). The most active molecule (4) doubled the stabilization 
temperature for tDRH whilst halving the quadruplex-stabilizing 
affinity, compared to NSC273829. Overall, the molecules had 
selective affinity for the tDRH sequence compared to other forms 
of DNA, particularly the standard DNA duplex (cDD). 
 
MD studies (S4, ESI) were undertaken using AMBER v11 
to rationalise the stabilisation observed in the FRET melting 
assay. It was observed that compounds with an even number of 
methylene spacers (i.e., compounds 2, 4 and 6) could bis-
intercalate between the bases more effectively compared to 
compounds with an odd number of methylene spacers (i.e., 1, 3 
and 5), which supported the experimental observations (Table 
1). More specifically, MD simulations suggested that in the case 
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of compounds with an even number of methylene spacers, both 
benzimidazole moieties are in the correct orientation to 
intercalate into the tDRH structure (Figure 5a), whereas an odd 
number of methylene spacers results in one benzimidazole 
moiety pointing out of the minor groove (Figure 5b).  Among 
the molecules examined, 4 provided the best stabilisation of the 
tDRH duplex sequence compared to NSC273829 (S4, ESI). A 
10 ns implicit solvent molecular dynamics simulation showed 
that the compound remained restrained over the sequence 5-
GTTAG-3 for the duration of the simulation due to favourable 
van der Waal’s interactions with the central 5-TTA-3 triplet 
(Figure 5a).  Simulations of 6 illustrated that this molecule binds 
to tDRH in a comparable manner to 4.  A similar intercalation 
interaction does not occur with NSC273829, which instead sits 
in the minor groove (Figure S4.2, ESI). The greater stabilisation 
of tDRH by 4 and 6 compared to NSC273829 was supported by 
free energy of binding calculations (kcal/mol) of the intercalation 
of Library 1 molecules and NSC273829 with tDRH and cDD 
sequences in implicit solvent (Table 2). Library 1 molecules 
were also assessed against a control DNA sequence in which the 
uracil (U) of the tDRH duplex sequence was replaced with 
thymine (T), in which case none of the designed molecules 
provided any notable stabilisation in the FRET melting assay.  
 
 
 
Figure 5: (a) Snapshot of a 10ns implicit solvent molecular 
dynamics simulation of 4 (blue spheres) interacting with tDRH. 
Both benzimidazole moieties intercalate into the sequence, one 
between G11:C20 and G10:C21 (green) and the second between 
A23:T8 and A24:T7 (yellow). (b) Snapshot of a 10 ns explicit 
solvent molecular dynamics simulation of 4 (blue and yellow 
spheres) interacting with the DNA duplex sequence (cDD). Both 
benzimidazole moieties orient away from the DNA groove. 
 
The molecular modelling results also supported the data from 
the biophysical experiments in suggesting that these molecules 
are unlikely to bis-intercalate into the control duplex DNA in an 
effective manner. First, a significant difference in topologies 
exists between the minor grooves of the DNA and tDRH 
duplexes.  The former has an enhanced curvature, whereas the 
tDRH minor groove is much flatter in its architecture. This 
difference in topology allows isohelical structures such as the 
polyamides (e.g., distamycin) to bind with high affinity in the 
duplex DNA minor groove, whereas NSC273829 and related 
molecules do not possess the appropriate curvature to interact 
with duplex DNA.  Second, Library 1 molecules were designed 
to possess a chair-like shape to match the topology of tDRH, and 
should induce binding through a dual mechanism of action (i.e., 
minor groove binding and intercalation). Therefore, the designed 
molecules may be able to selectively interact with the tDRH 
duplex through both modes. 
 
Table 2: Free energy of binding calculations (kcal/mol). 
Compound 
Free Energy of Binding (MM-PBSA†) 
tDRH  cDD  RRH 
4 -51.49 -48.27 -36.49 
6 -53.62 -49.44 -34.33 
NSC273829 -29.76 -35.59 -32.76 
†Molecular Mechanics Poisson Boltzmann Surface Area. 
 
Molecular models and free energy of binding calculations suggest 
that the binding of Library 1 molecules to RNA will most likely result 
in significant disorder of the nucleic acid structure, as the shape of 
compounds of this type is not consistent with RNA topology.  In the 
case of compound 4, both benzimidazole moieties point away from 
the RNA groove and do not participate in binding (Figure S4.3, ESI). 
This binding conformation results in base-pair displacement and 
strand separation which is reflected in the calculated free energies 
(i.e., less favourable than those obtained for cDD and tDRH). 
 
Next, a circular dichroism (CD) study was carried out to evaluate 
the interaction of the synthesized ligands with the tDRH structure (S5, 
ESI).  Little CD information is available in the literature relating to 
DNA/RNA hybrid duplexes, especially those originating in the 
telomeric region of DNA.  The CD spectrum of the tDRH duplex in 
Tris-HCl (50 mM) was initially measured, and an intense positive CD 
signal was observed at ~271 nm, along with a small negative CD 
signal at ~237 nm (Figure S5.1, ESI).  The CD spectrum of the control 
DNA duplex (cDD) showed a strong positive CD signal at ~269 nm 
and a negative signal at ~241 nm (Figure S5.1, ESI). Compounds 4 
and 6 induced significant changes in the positive CD signal at 237 nM, 
but did not cause any notable changes to the negative CD signal 
(Figure 6). A dose-dependent enhancement of the positive CD signal 
correlated well with the FRET melting results. For example, for 4 
(Figure 6a), dose-dependent red shifts of between 1.2 to 4 nM were 
observed after addition of up to 5 equivalents of the ligand. 
Interestingly, hypochromic shifts were observed for 4 which is 
unusual, as red shifts are usually associated with hyperchromic shifts.  
An isoelliptic point for the spectrum was observed for the different 
concentrations of the compounds, suggesting that the molecules are 
working through a similar but specific mode of action (i.e., bis-
intercalation). 
Figure 6: CD spectra of compound 4 (a) and 6 (b) with tDRH (5 μM) 
in Tris buffer (pH 7.4) at 0-5 equivalents ligand concentration. 
(a) 
(b) 
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Compound 6 produced a very similar CD titration profile (Figure 
6b) with dose-dependent red shifts and hypochromic effects.  
Addition of up to 5 equivalents of 4 and 6 to the cDD sequence did 
not produce any change in the CD signal (Figure S5.2, ESI). The 
shifts and changes in intensity observed for the tDRH sequence and 
the lack of interaction observed for the cDD sequence supported both 
the FRET-melting data and the molecular modelling results. 
 
The FRET melting assay, molecular modelling and dynamics 
studies along with the CD titration results support the hypothesis 
that Library 1 molecules stabilise the tDRH structure by bis-
intercalation. The Library 1 molecules were also found to 
interact with telomeric quadruplex-forming DNA (e.g., F21T) 
(Figure 1c) in the FRET studies (Table 1).  Molecular modelling 
studies suggest that they may be able to bind on the periphery of 
tDNA quadruplex structures (Figure S4.4, ESI) due to their 
curvature.  If developed as telomerase inhibitors, their telomeric 
quadruplex-binding properties may also contribute to their 
potency, as molecules that stabilise telomeric quadruplex 
structures are known to inhibit the telomerase enzyme. 
   
To provide further evidence for the proposed mechanism of 
action of binding to the tDRH duplex, and to generate 
structure-activity relationship (SAR) data, molecular 
modelling was used to guide the design of a number of 
molecules lacking the key features of Library 1 compounds 
(ESI, Table S6.1).  Key features were considered to be: i) the 
flexibility afforded by the methylene spacer, ii) the single 
methylene spacers between the benzimidazole and phenylene 
moieties, and iii) the planar structure of the terminal 
benzimidazole moieties. Thus, in Library 2 the methylene 
linkers were partly replaced with phenylene groups to provide 
rigidity to the linker, and in Library 3 the flexible methylene 
linker of the molecules was retained, but the terminal single 
methylene groups were removed and the terminal 
benzimidazole moieties replaced with 6-fluoro-2-
methylquinoline moieties.  Finally, in Library 4, an additional 
cyclohexyl ring was introduced (via 7-fluoro-1,2,3,4-
tetrahydroacridine) to remove planarity and prevent 
intercalation (Figure 7).  For Library 3 and 4 molecules, an 
identical length of central methylene spacers was used to 
produce the bis-amide products (Table S6.2, S6.3 and S6.4, 
ESI).  The library members were synthesized using similar 
amide coupling procedures to those described earlier. 
 
 
 
Figure 7: General structures of Libraries 2, 3 and 4. 
 
All molecules in Libraries 2, 3 and 4 were evaluated for their 
ability to stabilise tDRH based on FRET melting and CD. None 
produced any notable stabilisation (i.e., 1C) of the tDRH 
duplex at the highest concentration tested (i.e., 5 μM).  All 
molecules were found to be CD inactive.  This confirmed the 
importance of the key features of Library 1 molecules for 
interaction with the tDRH duplex. These results were consistent 
with the molecular modelling predictions, which suggested that 
the molecules lack the appropriate shape to intercalate into the 
tDRH structure, and should have only weak interactions in the 
minor groove of the A-form structure. The modelling also 
highlighted the importance of the flexibility of the central 
methylene spacers for bis-intercalation, as the rigid and planar 
phenylene (i.e., 7) and biphenylene (i.e., 8) containing 
compounds with identical terminal units to those used in 
Library 1, were unable to intercalate. 
 
Finally, Library 1 molecules were evaluated for their 
cytotoxicity in two tumour cell lines using a MTT assay (S7, 
ESI). In MDA-MB-231 and NCI H1975 cells (Table 3), 4 and 6 
produced low micromolar IC50 values after 48 hours incubation.  
The potency of compounds with an even number of methylene 
spacers was marginally higher compared to those with an odd 
number, consistent with the results of the biophysical and 
computational experiments. However, further studies are 
required to demonstrate that the observed cytotoxicity is 
associated with telomere maintenance in tumour cells. 
 
Table 3: IC50 values of Library 1 molecules after 48 hours incubation  
Compound 
IC50 Value (μM) * Mean (n = 3) 
MDA-MB-231  NCI H1975 
2 3.4  > 100 
3 4.2  16.8 
4 1.1  11.8 
5 9.2  15.3 
6 4.2  1.5 
 
In summary, a novel chemical scaffold has been identified 
capable of bis-intercalating into the tDRH structure, but with no 
affinity for duplex DNA due to its 3-dimensional shape. This 
offers an opportunity to selectively target the telomeric 
DNA/RNA duplex for therapeutic purposes while not affecting 
normal genomic DNA.  The ligands described here can be used 
as a starting point to generate more potent molecules while 
potentially retaining selectivity. In particular, there is the 
possibility of creating diversity in the terminal heterocyclic 
groups, which may also be modified to optimise drug-like 
characteristics. 
 
      ‡ ESI: Literature molecules (S1), Synthesis, Purification and 
Analysis (S2), FRET Assay (S3), Molecular modelling studies 
(S4), Modelling simulations of compound 6 (S4.1), NSC273829 
(S4.2) and compound 3 on quadruplex structure (S4.4), CD data 
(S5.2, S5.3, S5.4), Synthesized molecules and their 
characterization (S6), Synthesised Library 2, 3 and 4 molecules 
(S6.2, S6.3 and S6.4), Cytotoxicity assay (S7), 13C-NMR and 
HRMS data (S8).  
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